Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum

• US 20060130159A1
• Filed: 12/09/2004
• Published: 06/15/2006
• Est. Priority Date: 12/09/2004
• Status: Abandoned Application

• Current Assignee: GTC Biotherapeutics, Inc.
• Original Assignee: GTC Biotherapeutics, Inc.
• Inventors: Masiello, Nick, Perreault, Mark
• Application Number:
  US11/007,852
• Publication Number:
  US 20060130159A1
• Time in Patent Office: Days
• US Class Current: 800/7
• CPC Class Codes: C07K 14/445 Plasmodium
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of purifying MSP-1 from a variety of source materials including from the milk of transgenic mammals.

Claims

1. A method of purifying a merozite surface protein 1 (MSP-1) or a fragment thereof from a feedstream, comprising:

Solubilizing said merozite surface protein 1 from a feedstream utililizing a tangential flow filtration process;

Washing said filtrate on a membrane with a PBS solution wherein said MSP-1 or fragment thereof remains in the retentate on the purification column;

Adding an aqueous arginine or urea solution to said MSP-1 remaining in the retentate to solubilize it;

Eluting said MSP-1 from said purification column; and

,

Purifying out said MSP-1 from elution

2. The method of claim 1 further comprising regenerating a purification column after the addition of said arginine or urea solution by using an aqueous NaOH solution.

3. The method of claim 1 wherein said tangential flow filtration process also includes the use of an EDTA solution.

4. The method of claim 1 wherein the MSP-1 finally eluted from the column is thereafter stored at 4°

C.

5. The method of claim 1 wherein the resin used is selected from the list comprising POROS HS-50 resin;

CHT resin; and

, 30Q resin.

6. The method of claim 1 wherein said purification protocol has Tween 80 in the buffers.

7. The method of claim 1 wherein said purification protocol has no Tween in the buffers.

8. The method of claim 1 wherein said purification protocol has 0.05% Tween 80 in the buffers.

9. The method of claim 1 further comprising wherein a Q column is used as an initial flow through step prior to said Tangential Flow Filtration process.

10. The method of claim 1 wherein said arginine solution is between 0.2 and 1.0 M in concentration.

11. The method of claim 10 wherein said arginine solution is 0.6M in concentration.

12. The method of claim 1 wherein the clarified filtrate, after capture is then washed on a 500 kd MWCO membrane with PBS to remove the bulk of remaining proteins.

13. The method of claim 1 wherein said feedstream is milk.

14. The method of claim 1 wherein said tangential flow filtration process also includes the use of a membrane of sufficient pore size to retain milk fat while allowing the flow through of casein proteins.

15. The method of claim 1 wherein said membrane is at least 0.45 um in pore size.

16. The method of claim 1 wherein said merozite surface protein 1 (MSP-1) or a fragment thereof is produced in the milk of a non-human transgenic mammal

17. The method of claim 1 wherein said non-human transgenic mammal possesses a genome further comprising a modified nucleic acid encoding MSP-1 or fragment thereof operably linked to a promoter which directs expression in the mammary gland, wherein the nucleic acid has been modified by replacing at least one AT-containing codon of a wild-type nucleic acid sequence encoding MSP-1 with a preferred codon encoding the same amino acid as the replaced codon such that the AT-content of the modified nucleic acid is lowered as compared to the wild-type nucleic acid sequence encoding MSP-1.

18. The method of claim 1 wherein the material removed in the partial purification of step (b) is selected from the group consisting of lipids, small molecule contaminants, proteins other than MSP-1, bacterial contaminants, viral contaminants and any combination thereof.

19. The method of claim 18 wherein the material removed in the partial purification of step (b) is one or more of the materials selected from the group consisting of cream, casein, lipids, small molecule contaminants, and proteins other than MSP-1.